secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001082554-23-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics Q2 2023: revenue $596.5M (+28%), net income $259.2M (+123%)
-------------------------------------------------------------------------------

- Total revenues $596.5M (+28% YoY), net income $259.2M (+123%), diluted EPS $5.24.
- Tyvaso (including DPI) sales $318.9M, up 59% YoY, driven by patient growth and inventory build.
- Orenitram sales $95.1M (+20%); Remodulin sales $127.2M (-4% YoY).
- CEO expects $4B annual revenue run rate by mid-decade with continued expansion.
- Share-based comp expense fell 79% to $13.8M due to stock price performance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255423000024/0001082554-23-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255423000024/uthr-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001082554-23-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer